Product Images Aripiprazole

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Aripiprazole NDC 31722-830 by Camber Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure1 - Figure1

Figure1 - Figure1

The text is a table showcasing the effect of other drugs on Aripiprazole. It shows the fold change and 90% C1 of Aripiprazole when paired with different drugs that either inhibit or induce certain enzymes. The drugs listed include ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

Figure2 - Figure2

Figure2 - Figure2

The text provides a list of drugs that influence the effects of Aripiprazole, categorized based on CYP inhibitors, CYP inducers, gastric acid blockers, and others. The drugs listed include Ketoconazole, quinidine, Carbamazepine, Famotidine, Valproate, Lithium, and Lorazepam. Additionally, the text includes a chart that displays the fold change and 90% confidence interval for Dehydro-Aripiprazole under the influence of the interacting drugs. Overall, this text provides useful information for medical professionals who prescribe or administer Aripiprazole to their patients.*

Figure3 - Figure3

Figure3 - Figure3

Figure4 - Figure4

Figure4 - Figure4

This text contains a list of factors along with their effects on PK parameters of Avripiprazole medication. The factors include CYP206, poor vs. extensive metabolizer, gender, age, hepatic impairment, and renal impairment. The text also mentions fold change of Avripiprazole and 0% C in relation to the reference.*

Figure5 - Figure5

Figure5 - Figure5

This appears to be a table comparing the effects of different factors (such as gender, age, and impairment) on the metabolism of a drug called Aripiprazole. The table includes values for AUC (area under the curve) and maximum concentration (max) of the drug, as well as fold change and 90% confidence intervals for dehydro-Aripiprazole. Without additional context, it is difficult to provide a more detailed or specific description.*

Structure - Structure

Structure - Structure

aripi10mg30s

aripi10mg30s

This is a medication package for Aripiprazole in 10 mg tablets. It is only available with a prescription and comes with a Medication Guide that should be provided separately to each patient. The usual dosage can be found in the package's insert. The tablets should be stored in tightly closed containers at a temperature between 20°C to 25°C (68°F to 77°F), as specified by USP Controlled Room Temperature. The medication guide can be found at http://camberpharma.com/medication-guides. This package contains 30 tablets and the manufacturer is Camber Pharmaceuticals, Inc., located in Piscataway, NJ 08854. The batch coding is in an unvarnished area of 40 x 20mm. The Manufacturer License Number is SOMN/AP2009F/R 2057113 and the medication is made by Hetero Labs Limited, Unit V, Polepally, Jadcheria, Mahabubnagar - 509 301, India.*

aripi15mg30s

aripi15mg30s

This is a medication from Camber Pharmaceuticals called Aripiprazole. Each tablet has 15mg of the medication. It is only available through prescription and comes with a Medication Guide that should be dispensed to each patient by their pharmacist, as it contains important information about the drug. The standard dosage information can be found in the package insert. It should be stored between 20-25°C (68-77°F) in a tightly closed container. The medication is manufactured for Camber Pharmaceuticals by Hetero Labs Limited in India. A batch code can be found on the packaging.*

aripi20mg30s

aripi20mg30s

This is a prescription drug label for a tablet containing 20 mg Aripiprazole USP. The label provides the NDC, dosage instructions, storage information, and the manufacturer's contact number. The manufacturer is Camber Pharmaceuticals, Inc. The label has been scanned, and some text is unclear.*

aripi2mg30s

aripi2mg30s

Aripiprazole is a form of medication dispensed in tablets each containing 2mg of the drug. The medicine guide is provided separately for each patient and the usual dosage can be found in the package insert. The medication should be stored in tightly closed containers at a temperature of 68-77 degrees Fahrenheit. The manufacturer is Camber Pharmaceuticals and the medication is available in a package of 30 tablets. For batch coding purposes, there is an unvarnished area of 40 x 20mm. The drug is only available with a prescription and cannot be sold without one.*

aripi30mg30s

aripi30mg30s

This is a label for a medication called Aripiprazole Tablets, USP, with a concentration of 30mg per tablet. The pharmacist should dispense a separate medication guide to each patient. The recommended dosage is available in the package insert. The medication should be stored in tightly closed containers at controlled room temperature. Batch coding area is available for administrative purposes. The medication is manufactured by Hetero Labs Limited in India, for Camber Pharmaceuticals in Piscataway. A medication guide is also available online.*

aripi5mg30s

aripi5mg30s

Aripiprazole is a tablet medication in the USP that is usually prescribed in 5mg doses. It is dispensed with a medication guide separately provided for each patient by the pharmacist. It should be stored in tightly closed containers at a controlled temperature. Full prescribing information is included in the package insert. The medication guide is available at http://camberpharma.com/medication-guides. The manufacturer is Hetero Labs Limited, which is licensed to produce the medication for Camber Pharmaceuticals, Inc. Batch coding is available in an unvarnished area on the package.*

camber logo

camber logo

Figure-6 - figure 6

Figure-6 - figure 6

This is a description of a comparison study between the drug Aripiprazole and a placebo. The text shows a chart of the proportion of participants who experienced relapse over time, with the number of participants at risk indicated for each time point. The study lasted for at least 182 days after randomization.*

figure 7

figure 7

This is a graph that compares Avripiprazole with Placebo in terms of the proportion of patients with relapse over days from randomization. The x-axis displays the "Days from Randomization" and the y-axis represents the "Proportion with Relapse". The graph includes two lines; one represents Avripiprazole and another represents Placebo. There are also two tables with the numbers of subjects at risk for Avripiprazole and Placebo on the right side of the graph.*

figure 8

figure 8

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.